Jos H Beijnen (Jos Beijnen)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 13

Top Topics

Histone Deacetylase

End Stage Renal Disease

Cancer Stem Cells

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Pharmaceuticals (Basel, Switzerland)

Clinical and translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Alaa Embaby, Sanne C F A Huijberts, Liqin Wang, Rodrigo Leite de Oliveira, Hilde Rosing, Bastiaan Nuijen, Joyce Sanders, Ingrid Hofland, Charlaine van Steenis, Roelof J C Kluin, Cor Lieftink, Christopher G Smith, Christian U Blank, Johannes V van Thienen, John B A G Haanen, Neeltje Steeghs, Frans L Opdam, Jos H Beijnen, Alwin D R Huitema, René Bernards, Jan H M Schellens, Sofie Wilgenhof
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Alaa Embaby, Sanne C F A Huijberts, Liqin Wang, Rodrigo Leite de Oliveira, Hilde Rosing, Bastiaan Nuijen, Joyce Sanders, Ingrid Hofland, Charlaine van Steenis, Roelof J C Kluin, Cor Lieftink, Christopher G Smith, Christian U Blank, Johannes V van Thienen, John B A G Haanen, Neeltje Steeghs, Frans L Opdam, Jos H Beijnen, Alwin D R Huitema, René Bernards, Jan H M Schellens, Sofie Wilgenhof
A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600mutated melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Jonathan E Knikman, Marta Lopez-Yurda, Didier Meulendijks, Maarten J Deenen, Jan H M Schellens, Jos H Beijnen, Annemieke Cats, Henk-Jan Guchelaar
A nomogram to predict severe toxicity in DPYD wild-type patients treated with capecitabine-based anticancer regimens. Clinical pharmacology and therapeutics (2023)
David Damoiseaux, Alfred H Schinkel, Jos H Beijnen, Alwin D R Huitema, Thomas P C Dorlo
Predictability of human exposure by human-CYP3A4-transgenic mouse models: A meta-analysis. Clinical and translational science (2023)
Jonathan E Knikman, Tycho A Wilting, Marta Lopez-Yurda, Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, Didier M Meulendijks, Peter Nieboer, Helga J Droogendijk, Geert-Jan M Creemers, Caroline M P W Mandigers, Alexander L T Imholz, Ron H J Mathijssen, Johanneke E A Portielje, Liselot Valkenburg-van Iersel, Annelie Vulink, Marlene H W van der Poel, Arnold Baars, Jesse Joachim Swen, André B P van Kuilenburg, Jan H M Schellens, Jos H Beijnen, Henk-Jan Guchelaar, Annemieke Cats
Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Jing Wang, M Merve Susam, Changpei Gan, Rolf W Sparidans, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure. Pharmaceuticals (Basel, Switzerland) 15 (9) (2022)
Nancy H C Loos, Jos H Beijnen, Alfred H Schinkel
The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism? International journal of molecular sciences 23 (17) (2022)
Wenlong Li, Rolf W Sparidans, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel
ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability. Pharmaceutics 13 (11) (2021)
Yaogeng Wang, Rolf W Sparidans, Sander Potters, Rahime Şentürk, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel
P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO). Pharmaceuticals (Basel, Switzerland) 14 (11) (2021)
Mark T J van Bussel, Dick Pluim, Bojana Milojkovic Kerklaan, Mijke Bol, Karolina Sikorska, Dorothé T C Linders, Daan van den Broek, Jos H Beijnen, Jan H M Schellens, Dieta Brandsma
Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases. Neurology 94 (5) (2020)
Kimberley M Heinhuis, Nikki S IJzerman, Winette T A van der Graaf, Jan Martijn Kerst, Yvonne Schrage, Jos H Beijnen, Neeltje Steeghs, Winan J van Houdt
Neoadjuvant Systemic Treatment of Primary Angiosarcoma. Cancers 12 (8) (2020)
Johannes J M Rood, Amer Jamalpoor, Stéphanie van Hoppe, Matthijs J van Haren, Roeland E Wasmann, Manoe J Janssen, Alfred H Schinkel, Rosalinde Masereeuw, Jos H Beijnen, Rolf W Sparidans
Extrahepatic metabolism of ibrutinib. Investigational new drugs 39 (1) (2020)
Marie-Rose B S Crombag, Thomas P C Dorlo, Ellen van der Pan, Anoek van Straten, Andries M Bergman, Nielka P van Erp, Jos H Beijnen, Alwin D R Huitema
Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study. Pharmaceutical research 36 (12) (2019)